<DOC>
	<DOCNO>NCT00680654</DOCNO>
	<brief_summary>This study demonstrate safety , tolerability , pharmakokinetic pharmacodynamic effect BAY63-2521 patient pulmonary hypertension stable treatment sildenafil 20 mg .</brief_summary>
	<brief_title>Interaction Study Patients With Pulmonary Hypertension Stable Treatment Sildenafil 20 mg TID</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients pulmonary hypertension stable last 6 week Treated Sildenafil 3 Ã— 20 mg Undergoing routine invasive diagnostics . Preexisting lung disease pulmonary arterial hypertension , Acute severe chronic leave heart failure , Severe coronary artery disease , Uncontrolled arterial hypertension ; Congenital acquire valvular myocardial disease except acquire tricuspid valve insufficiency due pulmonary hypertension , Systolic blood pressure &lt; 100 mmHg , heart rate &lt; 55 bpm &gt; 105 bpm , PaO2/FiO2 &lt; 50 mmHg , PaCO2 &gt; 55 mmHg , Severe hepatic insufficiency , Severe renal insufficiency , Administration strong CYP3A4 inhibitor inductor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pulmonary hypertension</keyword>
</DOC>